REFRACTORY MYELODYSPLASTIC SYNDROME

This early-stage trial tests a new drug called Q702 in people with certain blood cancers or related diseases that have not responded to other treatments. The drug works by helping the immune system attack cancer cells and supporting normal blood cell production. The study will ch…

This study tests a combination of two drugs—CPX-351 (a liposomal form of standard chemotherapy) and quizartinib—in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to find the best dose and see if the combo can control the cancer. …

This study tests a new approach for adults with blood cancers like AML that have come back or not responded to treatment. Participants receive intense chemotherapy followed immediately by a donor stem cell transplant, plus drugs to prevent graft-versus-host disease. The goal is t…

This early-phase trial tests a combination of three drugs—pembrolizumab, decitabine, and venetoclax—in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the dr…

This early-stage study is testing a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with blood cancers MDS and AML. The goal is to find the safest dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment …

This study tests a new treatment for adults with aggressive blood cancers like acute myeloid leukemia (AML) that are hard to cure. Patients receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and total body radiation, followed by a stem cell transplant from a h…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug blocks a protein involved in inflammation that may help cancer grow. The goal is to see if it improves blood cou…

This study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 pa…

This early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…